Neoadjuvant FinHer regimen in patients with HER2-positive breast cancer: a retrospective audit - Takeaways - MDSpire

Neoadjuvant FinHer regimen in patients with HER2-positive breast cancer: a retrospective audit

  • By

  • Anoop T. M.

  • Rona Joseph

  • Sherin Mathew

  • Mintu Mathew

  • Saikumar Soman

  • Kalai Bharathi

  • Senthamizhan S

  • May 18, 2026

  • 0 min

Share

  • 1

    The neoadjuvant FinHer protocol achieved a pathological complete response (pCR) rate of 30% in locally advanced HER2-positive breast cancer patients.

  • 2

    Estrogen receptor (ER) and progesterone receptor (PR) positivity were significantly associated with decreased pCR rates in the study population.

  • 3

    Patients with the HER2-enriched subtype had higher pCR rates (47%) compared to those with the luminal B HER2-positive subtype (21.2%).

  • 4

    Stage III disease was the only significant predictor of disease-free survival (DFS) and overall survival (OS) in the analyzed cohort.

  • 5

    Achievement of pCR was linked to a numerically lower risk of death and recurrence, highlighting its importance in treatment outcomes.

Original Source(s)

Neoadjuvant FinHer regimen in patients with HER2-positive breast cancer: a retrospective audit

  • by Anoop T. M., Rona Joseph, Sherin Mathew, Mintu Mathew, Saikumar Soman, Kalai Bharathi, Senthamizhan S

  • May 18, 2026

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma